Brief: Hillstream Biopharma Receives Orphan Drug Designation For Hsb-1216 For The Treatment Of Uveal Melanoma
16/02/2022 15:34
Feb 16 (Reuters) - Hillstream Biopharma Inc HILS.O :
* HILLSTREAM BIOPHARMA RECEIVES ORPHAN DRUG DESIGNATION FOR
HSB-1216 FOR THE TREATMENT OF UVEAL MELANOMA
Source text for Eikon: urn:newsml:reuters.com:*:nGNX9c4xXK
Further company coverage: HILS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing